Ofatumumab’s Effect on Annualized Relapse Rate in Patients with MS: Jeffrey Cohen, MD
The neurologist in the Mellen Center for Multiple Sclerosis Treatment and Research at Cleveland Clinic, shares more on his late breaker presentation from the 38th ECTRIMS conference. [WATCH TIME: 4 minutes]
WATCH TIME: 4 minutes
“We consider the risk benefit for each patient individually. But I would say more and more the impression is that risk benefit relationship favors higher efficacy therapies for most people early and earlier in their treatment sequence.”
At the 38th2022 European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Congress (ECTRIMS) from October 26-28, in Amsterdam, Netherlands, Jeffrey Cohen, MD, presented a late breaker presentation on the comparison of clinical and MRI outcomes in patients who initiated ofatumumab (n = 946) in the ASCLEPIOS trial (NCT02792218) versus those who switched from teriflunomide (Aubagio; Sanofi) to ofatumumab (n = 936) in the ALITHIOS open label extension study (NCT03650114).1
Cohen, neurologist, Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic, and colleagues showed that switching from teriflunomide to ofatumumab in the extension significantly reduced the annualized relapse rate by 68.3–76.6%. Continued treatment into the extension resulted in a further reduction of annualized relapse rate (39.9–65.1%) for patients. In addition, the switch to ofatumumab or the continuation of the treatment was associated with a reduction in risk of 3- or 6-month-confirmed disability worsening.1
In an interview with NeurologyLive®, Cohen discussed his takeaways from the study presented at 2022 ECTRIMS. He spoke about a subgroup analysis from the open-label extension and his reactions to the findings. Additionally, he recommended a continued follow-up to gather data on patients in the extension study.
